MiNK Therapeutics (INKT) Operating Expenses (2020 - 2026)
MiNK Therapeutics (INKT) posted Operating Expenses of $2.9 million for Q1 2026, down 12.05% sequentially from $3.3 million in Q4 2025, and up 13.78% YoY from $2.5 million in Q1 2025.
MiNK Therapeutics (INKT) Operating Expenses (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $2.9 million in Q1 2026.
- Quarterly Operating Expenses rose 13.78% year-over-year to $2.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (up 37.24% YoY) and the FY2025 annual result came in at $12.5 million, up 17.25% from the prior year.
- Operating Expenses retreated to $2.9 million in Q1 2026 per INKT's latest filing, from $3.3 million in the prior quarter.
- Over five years, Operating Expenses peaked at $8.0 million in Q3 2022 and troughed at $1.7 million in Q3 2024.
- A 5-year average of $4.7 million and a median of $3.8 million in 2024 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 99.7% in 2022, then sank 67.38% in 2024.
- Over 5 years, Operating Expenses stood at $7.9 million in 2022, then tumbled by 30.28% to $5.5 million in 2023, then slumped by 59.73% to $2.2 million in 2024, then jumped by 47.93% to $3.3 million in 2025, then slipped by 12.05% to $2.9 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $2.9 million, $3.3 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | MiNK Therapeutics | 57.77 Mn | 57.77 Mn | - | 3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.22 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Dec 31, 2025 | 3.28 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 3.69 Mn |
| Mar 31, 2025 | 2.53 Mn |
| Dec 31, 2024 | 2.21 Mn |
| Sep 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 5.50 Mn |
| Sep 30, 2023 | 5.22 Mn |
| Jun 30, 2023 | 6.34 Mn |
| Mar 31, 2023 | 5.85 Mn |
| Dec 31, 2022 | 7.89 Mn |
| Sep 30, 2022 | 7.99 Mn |
| Jun 30, 2022 | 7.70 Mn |
| Mar 31, 2022 | 7.37 Mn |
| Dec 31, 2021 | 6.31 Mn |
| Sep 30, 2021 | 4.15 Mn |